20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Thymoquinone and Cancer Stem Cells: Targeting Tumor Recurrence

Cancer stem cells (CSCs) are a subpopulation of cells within tumors that possess stem-like properties, including self-renewal and the ability to differentiate into various cancer cell types. These CSCs are believed to play a significant role in tumor initiation, progression, metastasis, treatment resistance, and recurrence. Targeting CSCs is therefore a crucial strategy for achieving durable cancer remission.

Emerging research suggests that Thymoquinone (TQ), a natural compound from Nigella sativa, may have a significant impact on cancer stem cells. Preclinical studies have indicated that TQ can affect CSC populations in various cancer types, including breast cancer. These studies have shown that TQ can reduce the proportion of CSCs, often identified by markers like CD44+/CD24− in breast cancer cells.

The mechanisms by which TQ might target CSCs are still being explored but likely involve the modulation of pathways critical for stem cell function. CSCs often rely on specific signaling pathways, such as Wnt, Notch, and Hedgehog, for their self-renewal and survival. TQ's known ability to interfere with pathways like Wnt/β-catenin and PI3K/Akt may contribute to its effects on CSCs.

Furthermore, the resistance of CSCs to conventional chemotherapy is a major challenge in cancer treatment. TQ's potential to overcome this resistance, as seen in its synergistic effects with chemotherapy, could also extend to CSCs. By making CSCs more susceptible to treatment or by directly targeting their survival mechanisms, TQ could play a role in preventing tumor recurrence.

While the evidence is still primarily from preclinical research, the prospect of Thymoquinone targeting cancer stem cells offers a promising new avenue for cancer therapy. By addressing the root of tumor recurrence and resistance, TQ could contribute to more effective and long-lasting cancer treatment outcomes. Further research is essential to elucidate these mechanisms and translate these findings into clinical applications.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Exploring Thymoquinone's Impact on Cancer Cell Cycle and Apoptosis

Next: Thymoquinone: A Natural Immune Modulator for Cancer Therapy

All Rights Reserved